What is NCT04512345 (haloperidol decanoate) and why does it involve elderly people with schizophrenia?
NCT04512345 is a clinical trial record for haloperidol decanoate in the treatment setting of schizophrenia, with a focus that includes elderly participants. The trial identifier suggests a study registered on ClinicalTrials.gov, where the population and inclusion criteria are typically tied to age (elderly cohorts) and the schizophrenia diagnosis.
What are the key trial details to check for NCT04512345?
If you’re trying to interpret what the study will actually test in older adults, the most important fields on the trial record are usually:
- Eligibility criteria that define what “elderly” means for the study (often via age thresholds).
- Primary and secondary outcome measures (for example, symptom scales, relapse measures, or safety endpoints).
- Dosing schedule for haloperidol decanoate (monthly vs. other schedules) and how dose adjustments are handled in older patients.
- Recruitment status and estimated study dates, which determine whether results are already available or still pending.
- Safety monitoring specifics, which matter more in older adults due to higher risk for adverse effects from antipsychotics.
Are results posted yet for NCT04512345?
ClinicalTrials.gov records can show whether results are posted (and sometimes basic result summaries). The practical way to answer this is to look at the “Results” section and the “Study Results” posting status on the specific NCT page for NCT04512345.
What side effects or risks are older adults most concerned about with haloperidol decanoate?
Older adults starting or switching to long-acting haloperidol decanoate are commonly monitored for class-related antipsychotic risks, including:
- Motor side effects (extrapyramidal symptoms) and tardive dyskinesia.
- Sedation and falls risk.
- QT interval prolongation and cardiac rhythm risks (relevant for haloperidol).
- Metabolic changes (weight, glucose, lipids), though these vary by individual and drug.
- Increased vulnerability to adverse outcomes from antipsychotics in older populations, which often drives tighter safety monitoring protocols.
What would make a trial like this clinically useful for elderly schizophrenia patients?
A study focused on older adults typically aims to clarify one or more of the following:
- How well long-acting haloperidol decanoate controls schizophrenia symptoms in an elderly subgroup.
- Whether safety outcomes differ in older participants compared with younger populations.
- Whether a particular dosing strategy improves tolerability or reduces relapse compared with other approaches (depending on the trial design).
Where can you read the official trial record for NCT04512345?
To get exact information (population definitions, outcomes, status, and whether results exist), use the ClinicalTrials.gov listing for NCT04512345.
If you paste the text from the NCT04512345 page (or the “Brief Summary,” “Eligibility,” and “Outcomes” sections), I can translate it into a clear plain-English explanation tailored to your question about elderly schizophrenia and haloperidol decanoate.
Sources
No sources were provided with your message (and I don’t have the NCT record text itself).